Abstract
BackgroundThe relation between PIM2 and the transcriptional factor NF κβ have been controversial in literature. The significance of PIM2 and NF-κβ genes expression on the incidence of acute leukemia (AML and ALL) and its relevance to the response rate was evaluated. Sixty de novo acute leukemia patients were stratified in 2 groups: 30 acute myeloid leukemia (AML) and 30 acute lymphoblastic leukemia (ALL) patients and compared to 30 sex- and age-matched controls. The expression level of PIM2 and NF κβ genes was measured using quantitative real-time polymerase chain reaction (QRT-PCR). The patients were followed with clinical examination and complete blood counts.ResultsThe expression level of PIM2 gene was significantly higher in AML patients (P<0.001) compared to the control group. The mean expression level of NF κβ gene was significantly high in AML and ALL patients compared to the healthy control group (P=0.037 and P<0.001; respectively). The overall survival in AML patients was higher in NF κβ gene low expressers compared to high expressers (P=0.047). The number of AML patients who achieved complete remission was significantly higher in PIM2 gene low expressers in comparison to PIM2 gene high expressers (P=0.042).ConclusionPIM2 and NF κβ genes might have a role in the pathogenesis of acute leukemia, poor overall survival, and failure of response to induction therapy.
Highlights
The relation between PIM2 and the transcriptional factor NF κβ have been controversial in literature
The mean level of PIM2 gene expression was significantly higher in the acute myeloid leukemia (AML) patients compared its expression level in the healthy control group (P
The mean level of expression of NF κβ was significantly higher in AML and acute lymphoblastic leukemia (ALL) groups compared to the control group (P=0.0371, P
Summary
The relation between PIM2 and the transcriptional factor NF κβ have been controversial in literature. The significance of PIM2 and NF-κβ genes expression on the incidence of acute leukemia (AML and ALL) and its relevance to the response rate was evaluated. Resistance to treatment represents the main reason patients are not cured. Acute lymphoblastic leukemia (ALL) encompasses a group of lymphoid neoplasms. These disorders are classified by the WHO as B-lymphoblastic or Tlymphoblastic leukemia/lymphoma. These leukemic processes of these neoplasms is associated with the involvement of the peripheral blood, bone marrow, or may be limited to the infiltration of tissues with absent or limited (less than 20%) bone marrow association [3]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.